out gastric malignancy through work-up based on patient's complaints.
Upper gastrointestinal endoscopy report revealed proliferative lesion, edematous mucosa with ulceration occupying anterior stomach wall, and lesser curvature of distal gastric body. Computed tomography abdomen report was suggestive of gastroduodenal tumor, moderate ascites, and perigastric omental nodules. Gastroduodenoscopy report revealed tumor along lesser curvature extending to and deforming the pylorus and duodenum. Thus, provisional diagnosis was gastric malignancy with SMJN.
Umbilical nodule biopsy confirmed the diagnosis of metastatic adenocarcinoma [ Figure 3 ]. Gastroscopic biopsy of tumor at lesser curvature/distal gastric body revealed adenocarcinoma (diffusely infiltrating type). Finally, the patient was subjected to gastrectomy, local lymph node/umbilical, and omental nodules' resection after neoadjuvant chemotherapy, and the above biopsy diagnosis was confirmed on the larger specimen [ Figure 4 ].
Currently, the patient is under regular follow-up and advised chemotherapy cycles.
discussion
Sir Hamilton Bailey coined the word "SMJN" for the umbilical metastasis of an abdominal malignancy in 1948. [2] The mean age of SMJN diagnosis is approximately 50 years, with a range of 18-87 years. [3] Our patient was a 68-year-old male.
Among all malignant umbilical lesions, about 12% are primary tumors, whereas 88% are metastatic (SMJN). [2] SMJN is reported as the first presentation of primary malignancy in 15%-30% of cases. [2] SMJN has a poor prognosis, with average survival of 6 months after onset of umbilical metastasis. [4] SMJN can be categorized as metastasis from GI malignancies (35%-65%), genitourinary tract (12%-35%), unknown tumor sites (15%-30%), and those from lung and breast (3%-6%). [5] Among GI tract malignancies, common sites in decreasing order of frequency are stomach (25%), colorectal (10%), and pancreas (7%). Among the prominent histological type is adenocarcinoma (75%), with 15% comprised of other tumor types such as squamous cell carcinoma, undifferentiated tumors, sarcoma, carcinoid, mesothelioma, lymphoma, and melanoma. [1, 3, 5, 6] An umbilical tumor is benign (57%) or malignant (43%). SMJN has to be differentiated from benign umbilical lesions which include umbilical hernia, umbilical endometriosis, pilonidal sinus, hypertrophic scar, pyogenic granuloma, lymphangioma, omphalitis, fibroma, foreign body granuloma, mycosis, papillomas, keloids, myxoma, nevi (most common benign tumor), epithelial inclusion cysts, urachal duct sinus, and dermatofibroma. [1, 3] Apart from malignant melanoma, which is the most common primary umbilical malignancy, other primary malignancies include basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, and sarcoma. Furthermore, mycosis fungoides (non-Hodgkin's lymphoma) requires special mention as a differential to SMJN. It is a primary T-cell lymphoma involving skin. However, rather than umbilicus epidermis, the subepithelial tissue was showing the primary tumor in our case. Primary umbilical adenocarcinoma is assumed to arise from ectopic remnants of urachus. [3, [5] [6] [7] Tumor may spread to the umbilicus through lymph ducts, blood vessels, contiguous extension, and embryologic remnants. This may be the first clinical manifestation of occult visceral cancer, or it indicates tumor recurrence. [8] [9] [10] FNAC is a cost-effective, simple procedure to diagnose SMJN just like in our case. It must be followed by extensive workup for the diagnosis of the primary tumor. [5] In our case, we diagnosed it as SMJN on 1 st day of admission and advised to rule out primary gastric malignancy, based on clinical correlation.
Biopsy (gold standard test) of SMJN revealed the diagnosis of adenocarcinoma metastasis, whereas guided biopsy of gastric lesions revealed primary gastric adenocarcinoma after 4 days of patient's admission.
The average time between diagnosis of SMJN/skin manifestation and primary cancer is 3 months. The mean life expectancy without any treatment is 2-11 months. Fewer than 15% of such patients live beyond 2 years. Survival of such cases is better when a combination of neoadjuvant chemotherapy; surgery is given to the patient (21 months) or instead of chemotherapy alone (10.3 months) or instead of surgery alone (7.4 months). Thus, treatment must be individualized based on the clinical status of patient. Our patient was subjected to neoadjuvant chemotherapy followed by gastrectomy and wide local resection of umbilical nodule. [7] conclusion We infer that identification of SMJN is still an important clinical sign even in this era of modern technology. High degree of clinical suspicious is required to diagnose it, as most umbilical nodules are metastatic, unless proven otherwise. We suggest the simple, time-saving, initial FNAC procedure as mandatory to establish SMJNs diagnosis and to guide the search for primary malignancy on workup of patient. Subsequent guided biopsy from the primary tumor will help to give a definitive diagnosis. Treatment (surgery with chemotherapy) gives better results of survival. Regular follow-up is important after surgery.
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